Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
GRAIL Inc.

GRAIL Inc. (GRAL) Stock Overview

Explore GRAIL Inc.’s financial performance, market position, analyst ratings, and future outlook.

GRAL●NASDAQ
HealthcareBiotechnology
$64.42
$2.35(3.52%)
U.S. Market opens in 16h 46m

GRAIL Inc. (GRAL)

Meyka AI Score

Z

Key Financials

Market Cap2.8B
P/E Ratio-6.53
EPS (TTM)$-10.37
ROE-0.16%
Fundamental Analysis

AI Price Forecasts

1 Month$66.50
3 Months$110.32
1 Year Target$111.73

GRAL Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of GRAIL Inc. (NASDAQ: GRAL) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, GRAIL Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of GRAL on the NASDAQ shows an RSI of 47.78, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $111.73 for the NASDAQ listing.

Key metrics behind GRAIL Inc.'s NASDAQ-traded stock include a P/E ratio of -6.53 and a market capitalization of 2.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of GRAL on the NASDAQ.

Price Performance (NASDAQ: GRAL)

1-Day Change
-3.52%
5-Day Change
-7.83%
1-Month Change
-2.28%
3-Month Change
23.41%
6-Month Change
-36.22%
Year-to-Date (YTD) Change
-24.73%
1-Year Change
68.33%
3-Year Change
371.60%
5-Year Change
371.60%
All-Time (Max) Change
371.60%

Contact Information

http://www.grail.com
833-694-2553
1525 O’Brien Drive, Menlo Park, CA, 94025

Company Facts

9,100 Employees
IPO DateJun 12, 2024
CountryUS
Actively Trading

Frequently Asked Questions